ArticleBlood cancer journal2026

Post-transplant hypomethylating agents plus venetoclax maintenance improves survival in high-risk myeloid malignancies: A matched cohort study.

Haley Thigpen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.